VBI Vaccines Inc. (VBIVQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0005
0.00 (0.00%)
Oct 30, 2024, 9:59 AM EDT
VBI Vaccines Revenue
VBI Vaccines had revenue of $1.21M in the quarter ending March 31, 2024, with 150.31% growth. This brings the company's revenue in the last twelve months to $9.41M, up 553.09% year-over-year. In the year 2023, VBI Vaccines had annual revenue of $8.68M with 702.40% growth.
Revenue (ttm)
9.41M
Revenue Growth
+553.09%
P/S Ratio
0.00
Revenue / Employee
69.71K
Employees
138
Market Cap
14.34K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8.68M | 7.60M | 702.40% |
| Dec 31, 2022 | 1.08M | 451.00K | 71.47% |
| Dec 31, 2021 | 631.00K | -430.00K | -40.53% |
| Dec 31, 2020 | 1.06M | -1.16M | -52.23% |
| Dec 31, 2019 | 2.22M | -1.13M | -33.80% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.69B |
| Ryman Healthcare Limited | 411.39M |
| Verano Holdings Corp. | 920.97M |
| Vireo Growth Inc. | 98.04M |
| Medexus Pharmaceuticals Inc. | 108.78M |
VBI Vaccines News
- 3 months ago - Dow Jumps Over 300 Points; US Trade Gap Narrows In June - Benzinga
- 3 months ago - VBI Vaccines provides restructuring proceedings update - Seeking Alpha